Dave Stanforth

Statistics

Publications

Citations

1.8K

H-Index

Active since

2016

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Agilent Technologies (United States)

Dave Stanforth is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in immune checkpoint inhibitors, immuno-oncology biomarkers, and oncology.

Publications per year

2016–2017

Publications

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Fred R. Hirsch, Abigail McElhinny, Dave Stanforth et al. · Journal of Thoracic Oncology · 2016 · 1.3K citations · Full text

Medicine, Cancer Biology, Oncology +14

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer

Charlotte Roach, Nancy R. Zhang, Ellie Corigliano et al. · Applied immunohistochemistry & molecular morphology · 2016 · 353 citations · Full text

Medicine, Oncology, Pathology +17

Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1

Marisa Dolled‐Filhart, Charlotte Roach, Grant Toland et al. · Archives of Pathology & Laboratory Medicine · 2016 · 117 citations

Medicine, Oncology, Pathology +17

Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx.

Karina Kulangara, Debra Hanks, Stephanie Waldroup et al. · Journal of Clinical Oncology · 2017 · 90 citations

Medicine, Oncology, Pathology +17

1–4 of 4